Zhao Qiulong, Wang Chunxue, Cheng Jiaxin, Yan Hui, Wang Ling, Qian Dawei, Duan Jinao
Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing 210023, China.
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resource Industrialization, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization, Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
J Anal Methods Chem. 2022 Jul 2;2022:2565494. doi: 10.1155/2022/2565494. eCollection 2022.
According to the sixth edition of China's "New Coronavirus Diagnosis and Treatment Plan (NCDTP)," ReDuNing injection (RDN) was firstly introduced to treat severe and critical COVID-19, whereas its combination with broad-spectrum antibiotics was suggested to take with extreme caution and full reasons. Therefore, we aim to describe the pharmacokinetics of seven active phytochemicals and semiquantification of nine relevant metabolites in ReDuNing injection (RDN) after combining with cefuroxime sodium (CNa) for injection in rat plasma. Male Sprague-Dawley rats were randomly assigned to six groups, and they were intravenously administered, respectively, with different prescriptions of RDN (2 mL/kg) and CNa (225 mg/kg). At different time points (0.03, 0.08, 0.17, 0.24, 0.33, 0.50, 0.67, 1, and 6 h) after administration, the drug concentrations of iridoids glycosides, organic acids, and metabolites in rat plasma were determined using ultrahigh-pressure liquid chromatography coupled with linear ion rap-orbitrap tandem mass spectrometry (UHPLC-LTQ-Orbitrap-MS), and main pharmacokinetic parameters were estimated by noncompartment model. The results showed that there were differences in pharmacokinetic parameters, AUC, T, , CL of iridoids glycosides, and organic acids, after the intravenous administration of the different combinations of RDN and CNa. Moreover, different combinations of the injections also resulted in different curves of relative changes of each metabolite. The obtained results suggested that RDN and CNa existed pharmacokinetic drug-herb interactions in rats. The findings not only lay the foundation for evaluating the safety of RDN injection combined with CNa but also make contributions to clinically applying RDN injection combined with CNa, which works potentially against severe forms of COVID-19.
根据中国《新型冠状病毒肺炎诊疗方案(试行第六版)》,热毒宁注射液首次被用于治疗重型、危重型新型冠状病毒肺炎,但其与广谱抗生素联用需谨慎并说明充分理由。因此,我们旨在描述热毒宁注射液(RDN)与注射用头孢呋辛钠(CNa)联合后,大鼠血浆中7种活性植物化学成分的药代动力学及9种相关代谢产物的半定量情况。将雄性Sprague-Dawley大鼠随机分为6组,分别静脉注射不同处方的RDN(2 mL/kg)和CNa(225 mg/kg)。给药后不同时间点(0.03、0.08、0.17、0.24、0.33、0.50、0.67、1和6 h),采用超高效液相色谱-线性离子阱-轨道阱串联质谱法(UHPLC-LTQ-Orbitrap-MS)测定大鼠血浆中环烯醚萜苷、有机酸及其代谢产物的药物浓度,并通过非房室模型估算主要药代动力学参数。结果显示,静脉注射不同组合的RDN和CNa后,环烯醚萜苷和有机酸的药代动力学参数、AUC、T、Cmax、CL存在差异。此外,不同注射组合还导致各代谢产物相对变化曲线不同。所得结果表明,RDN与CNa在大鼠体内存在药代动力学药物-草药相互作用。这些发现不仅为评估RDN注射液与CNa联用的安全性奠定了基础,也为临床应用RDN注射液与CNa联用治疗重型新型冠状病毒肺炎做出了贡献。